Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
05
04
2021
accepted:
31
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Targeted drug delivery is one of the most intriguing and challenging issues in modern biomedicine. For active targeting, full-size IgG molecules (150 kDa) are usually used. Recent studies have revealed that small artificial polypeptide scaffolds such as DARPins (14 kDa) and affibodies (8 kDa) are much more promising tools for drug delivery due to their small size, artificial nature, low immunogenicity, and many other properties. However, there is no comparative information on the targeting abilities of scaffold polypeptides, which should be taken into account when developing drug delivery systems (DDSs). The present work is the first comprehensive study on the comparison of the effectiveness of different HER2-targeting proteins within the architecture of nanoparticles. Namely, we synthesized trimodal nanoparticles: magnetic, fluorescent, and directed toward HER2 oncomarker on cancer cells. The magnetic particles (MPs) were covalently modified with (i) full-size IgG, 150 kDa, (ii) DARPin_G3, 14 kDa, and (iii) affibody Z
Identifiants
pubmed: 34179645
doi: 10.1021/acsomega.1c01811
pmc: PMC8223436
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16000-16008Informations de copyright
© 2021 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Cell Sci. 2006 Jan 1;119(Pt 1):85-95
pubmed: 16352662
ACS Appl Mater Interfaces. 2019 Sep 25;11(38):34645-34651
pubmed: 31448887
Nanoscale. 2019 Jan 23;11(4):1636-1646
pubmed: 30644955
ACS Appl Mater Interfaces. 2018 May 23;10(20):17437-17447
pubmed: 29701945
PLoS One. 2013;8(3):e59163
pubmed: 23527120
Nanomedicine (Lond). 2015;10(8):1343-59
pubmed: 25955127
Bioeng Transl Med. 2019 Sep 05;4(3):e10143
pubmed: 31572799
J Mol Biol. 2008 Oct 24;382(5):1211-27
pubmed: 18706916
Chem Rev. 2017 Oct 11;117(19):12133-12164
pubmed: 28898067
Nanoscale. 2016 Jul 7;8(25):12764-72
pubmed: 27279427
Mol Cancer Res. 2008 Mar;6(3):491-500
pubmed: 18337455
Biomaterials. 2013 Apr;34(11):2796-806
pubmed: 23343632
J Mol Biol. 2007 Jun 15;369(4):1015-28
pubmed: 17466328
Nanomedicine. 2020 Jul;27:102197
pubmed: 32275958
Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(1):H164-H167
pubmed: 31172808
J Microsc. 2011 Apr;242(1):46-54
pubmed: 21118230
Infect Disord Drug Targets. 2017;17(3):149-159
pubmed: 28595539
Cancer Res. 2006 Apr 15;66(8):4339-48
pubmed: 16618759
Nat Biomed Eng. 2020 Jul;4(7):717-731
pubmed: 32632229
ACS Nano. 2020 Oct 27;14(10):12781-12795
pubmed: 32935975
Nanomedicine (Lond). 2018 Apr;13(8):953-971
pubmed: 29376469
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15039-44
pubmed: 20696930
Trends Biotechnol. 2015 Jul;33(7):408-18
pubmed: 25931178
Acta Naturae. 2019 Oct-Dec;11(4):42-53
pubmed: 31993234
Acta Naturae. 2015 Jul-Sep;7(3):126-32
pubmed: 26483969
Mater Today (Kidlington). 2020 Jul-Aug;37:112-125
pubmed: 33093794
Mol Biol Cell. 2013 Jan;24(2):129-44
pubmed: 23154999
Cancer Biol Ther. 2007 Dec;6(12):1960-6
pubmed: 18075296
Contrast Media Mol Imaging. 2012 May-Jun;7(3):308-19
pubmed: 22539401
Sci Rep. 2014 Jul 28;4:5840
pubmed: 25068300
Mol Pharm. 2019 Mar 4;16(3):995-1008
pubmed: 30608701
Small. 2015 Mar 25;11(12):1409-13
pubmed: 25418741
J Mater Chem B. 2017 Nov 21;5(43):8554-8562
pubmed: 32264523
Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111717
pubmed: 33545869
Sci Rep. 2017 Feb 22;7:43006
pubmed: 28223691
Cancers (Basel). 2020 Oct 16;12(10):
pubmed: 33081407
J Am Chem Soc. 2018 Oct 24;140(42):13550-13553
pubmed: 30351141
Small. 2010 Nov 5;6(21):2460-8
pubmed: 20925038
Mol Biol Cell. 2004 Dec;15(12):5268-82
pubmed: 15385631
Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11
pubmed: 11706390
Nanomedicine. 2013 Feb;9(2):194-201
pubmed: 22687896
Nanotechnology. 2010 Jul 16;21(28):285105
pubmed: 20585157
EJNMMI Res. 2020 Mar 23;10(1):21
pubmed: 32201920
Theranostics. 2019 Jan 24;9(3):778-795
pubmed: 30809308
Future Med Chem. 2018 Nov;10(22):2659-2674
pubmed: 30499740
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Dokl Biochem Biophys. 2015;464:315-8
pubmed: 26518557
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):619-30
pubmed: 26692551
Small. 2014 Feb 12;10(3):544-55
pubmed: 24038985
Biomaterials. 2017 Dec;147:86-98
pubmed: 28938164